未登录

C

Christopher Polk

AdventHealth Orlando

H指数:9

被引数:624

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluation of a health system's implementation of a monkeypox care model under the RE-AIM framework

THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE

IF3.4

2023-03-083

OAAI

Global monkeypox case hospitalisation rates: A rapid systematic review and meta-analysis

ECLINICALMEDICINE

IF10

2022-12-0128

OAAI

C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR' trial

IF7.7

2022-07-068

OAAI

Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

LANCET RESPIRATORY MEDICINE

IF32.8

2022-03-0153

OAAI

C-REACTIVE PROTEIN AS A BIOMARKER FOR IMPROVED EFFICACY OF LENZILUMAB IN COVID-19 PATIENTS: RESULTS FROM THE LIVE-AIR TRIAL

IF7.7

2021-11-080

PRE

LENZILUMAB EFFICACY AND SAFETY IN NEWLY HOSPITALIZED COVID-19 SUBJECTS: RESULTS FROM THE LIVE-AIR PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL

IF7.7

2021-11-0821

OA

C-REACTIVE PROTEIN AS A BIOMARKER FOR IMPROVED EFFICACY OF LENZILUMAB IN PATIENTS WITH COVID-19: RESULTS FROM THE LIVE-AIR TRIAL

IF8.6

2021-10-012

OAAI

Implementation of a comprehensive intervention focused on hospitalized patients with HIV by an existing stewardship program: successes and lessons learned

THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE

IF3.4

2021-04-193

OAAI

Skin and Soft Tissue Infections in Patients with Diabetes Mellitus

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

IF4.1

2021-03-0149

PREAI

Cryptococcus meningitis mimicking cerebral septic emboli, a case report series demonstrating injection drug use as a risk factor for development of disseminated disease

BMC INFECTIOUS DISEASES

IF3

2020-05-2713

OAAI

Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections

美罗培南-瓦硼巴坦与头孢他啶-阿维巴坦治疗耐碳青霉烯类肠杆菌科细菌感染的比较

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2020-04-21133

OAAI

The Impact of Continuation or Initiation of Combination Antiretroviral Therapy in People Living with HIV Presenting with Acute Septic Shock

AIDS PATIENT CARE AND STDS

IF3.8

2018-09-010

PREAI

A Nontraumatic Surprise Neck Mass

CLINICAL INFECTIOUS DISEASES

IF7.3

2016-09-120

OAAI

Induction therapy with enfuvirtide-based highly active antiretroviral therapy in a patient with acute HIV-1 infection

AIDS PATIENT CARE AND STDS

IF3.8

2007-02-011

PREAI